Dopamine D2 Receptor

Dopamine (DA) is a monoamine neurotransmitter with distinct functional roles across four major CNS projection systems: the mesolimbic pathway (nucleus accumbens — reward, motivation, positive symptoms of psychosis), mesocortical pathway (prefrontal cortex — executive function, working memory, negative symptoms), nigrostriatal pathway (basal ganglia — motor coordination, extrapyramidal function), and tuberoinfundibular pathway (hypothalamus-pituitary — prolactin regulation). The dopamine D2 receptor (D2R) is a Gi-coupled GPCR whose blockade in the mesolimbic system is the primary mediator of antipsychotic efficacy; however, D2R blockade in the nigrostriatal and tuberoinfundibular pathways produces extrapyramidal symptoms (EPS) and hyperprolactinaemia respectively — defining the tolerability challenges of antipsychotic therapy.

First-generation (typical) antipsychotics such as haloperidol are potent D2R antagonists with high receptor occupancy (70-80%), providing effective positive symptom control but with significant EPS liability and persistent hyperprolactinaemia. Second-generation (atypical) antipsychotics differ in their D2R binding kinetics and receptor binding profiles — the serotonin-dopamine antagonist model (5-HT2A blockade with D2R blockade) was the original explanatory framework, though subsequent receptor pharmacology research has identified fast D2R dissociation kinetics (the fast-off theory) and partial agonism as additional differentiating mechanisms. Clozapine, with low D2 affinity but broad receptor binding (D4, 5-HT2, M, H1, alpha-1), remains the only antipsychotic with demonstrated efficacy in treatment-resistant schizophrenia but requires mandatory haematological monitoring due to agranulocytosis risk.

Dopamine partial agonists (aripiprazole, cariprazine, brexpiprazole) act as functional antagonists in hyperdopaminergic states (mesolimbic) while providing partial agonist activity in hypodopaminergic states (mesocortical), offering a mechanistic rationale for improved negative symptom and cognitive domain management. In Parkinson's disease, dopamine agonists (pramipexole, ropinirole, rotigotine) directly stimulate dopaminergic receptors to compensate for nigrostriatal dopamine depletion, with rotigotine available as a transdermal patch enabling 24-hour dopaminergic stimulation. Impulse control disorders are a recognised class effect of dopamine agonist therapy requiring proactive counselling.